Table 4 Acute adverse events and grade for concurrent chemotherapy
Event for acute chemotherapy toxicity | Taxane combined platinum-based concurrent chemoradiotherapy N = 104 | |||||
|---|---|---|---|---|---|---|
All grades | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
Leukopenia | 72 (69.2%) | 30 (28.8%) | 32 (30.8%) | 9 (8.7%) | 1 (1.0%) | 0 (0.0%) |
Neutropenia | 37 (35.6%) | 13 (12.5%) | 16 (15.4%) | 4 (3.8%) | 4 (3.8%) | 0 (0.0%) |
Anemia | 35 (33.7%) | 34 (32.7%) | 1 (1.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Thrombocytopenia | 6 (5.8%) | 5 (4.8%) | 1 (1.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Hyper creatinine | 3 (2.9%) | 3 (2.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Total bilirubin elevation | 17 (16.3%) | 12 (11.5%) | 5 (4.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Conjugated bilirubin concentration elevation | 16 (15.4%) | 10 (9.6%) | 6 (5.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Unconjugated bilirubin concentration elevation | 16 (15.4%) | 11 (10.6%) | 5 (4.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Hyponatremia | 21 (20.2%) | 17 (16.4%) | 4 (3.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Hypochloremia | 19 (18.3%) | 16 (15.4%) | 3 (2.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Hypokalemia | 19 (18.3%) | 15 (14.4%) | 3 (2.9%) | 1 (1.0%) | 0 (0.0%) | 0 (0.0%) |
Nasopharyngeal wall necrosis | 3 (3.5%) | 0 (0.0%) | 1 (2.4%) | 0 (0.0%) | 0 (0.0%) | 2 (2.4%) |
Eye damage | 16 (18.8%) | 13 (15.3%) | 3 (13.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Deafness | 43 (50.6%) | 17 (20%.0) | 21 (24.7%) | 4 (4.7%) | 1 (1.2%) | 0 (0.0%) |
Trismus | 11 (12.9%) | 5 (5.9%) | 5 (5.9%) | 1 (1.2%) | 0 (0.0%) | 0 (0.0%) |
Xerostomia | 57 (67.1%) | 30 (35.3%) | 26 (30.6%) | 1 (1.2%) | 0 (0.0%) | 0 (0.0%) |
Skin damage | 29 (34.1%) | 23 (27.1%) | 6 (7.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Dysphagia | 15 (17.6%) | 13 (15.3%) | 2 (2.4%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Temporal-lobe necrosis | 17 (20.0%) | 16 (18.8%) | 1 (1.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |